Peptides

Peptides are short biomolecular agents used here as gynecological cancers immunotargeting tools, with a primary function of improving the success and safety of treatments through targeted delivery and recognition. In this context, they are being developed for drug targeting, cancer imaging, vaccines, peptide-drug conjugates, receptor-targeting therapies, and CAR-T therapies, and they are specifically discussed for cervical cancer, endometrial cancer, and ovarian cancer. A 2026 Translational Oncology review (PMID:41930712) frames them as next-generation immunotargeting agents, while PocketXMol-generated peptides can bind pd l1 for probing and therapeutic applications (PMID:41713417). Beyond oncology, topical peptide-based approaches are also mentioned in an integrative “In and Out” strategy for skin longevity and regeneration (PMID:41926038). Overall, the entry highlights peptides as a versatile platform spanning immunotargeting, molecular imaging, and therapeutic delivery, with PD-L1-binding design and gynecologic cancer applications as notable recent advances.

Gynecological cancers

  • A 2026 Translational Oncology review described peptides as next-generation immunotargeting agents for gynecological cancers, emphasizing their potential to improve treatment success and safety. (PMID:41930712)
  • Peptide-based immunotargeting was discussed for cervical cancer in gynecologic oncology. (PMID:41930712)
  • The same review included applications in endometrial cancer and ovarian cancer, extending peptide targeting across major gynecologic malignancies. (PMID:41930712)
  • Reported use cases included drug targeting, imaging cancer, vaccines, peptide-drug conjugates, receptor-targeting therapies, and CAR-T therapies. (PMID:41930712)

Molecular targeting and therapeutic design

  • PocketXMol was used to generate peptides that bind pd l1, supporting both probing and therapeutic applications. (PMID:41713417)
  • The PD-L1-binding result highlights peptide design for immune checkpoint-related targeting. (PMID:41713417)
  • These generated peptides illustrate how computational molecular generation can accelerate peptide discovery for receptor-specific binding. (PMID:41713417)

Dermatology and regeneration

  • Peptide-based topical treatments were discussed as part of an integrative “In and Out” approach for skin longevity and regeneration. (PMID:41926038)
  • This suggests peptide use beyond oncology, including dermatologic regeneration strategies. (PMID:41926038)